Summary
372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC) , which affects 3 out of 4 women at some point in their lives. Despite therapeutic advances, VVC remains a common problem worldwide, affecting all strata of society and being the second largest gynaecological infection. If it is left untreated, many complications have been appointed as its consequence, such as infertility, subsequent preterm delivery, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, pelvic abscess, menstrual disorders and miscarriage.
Avodes has developed an innovative medical device for menstruation - a patented anatomically shaped “moist sponge” made of completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal microflora during most vulnerable period – menstruation. Studies have shown, that fluctuating hormones and the resulting imbalance of vaginal flora cause an increased risk of a yeast infection every month. Unique Avodes biotechnological solution preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It reduces risk of vulvovaginal candidiasis (VVC) by 85 % thus effectively preventing the disease. Avodes is the only medical product designed to prevent infection, rather than deal with the consequences. Avodes effectively disrupts the vicious cycle of ”microbiota disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance” and offers break-through solution which protects women’s health and the environment.
Women Tech EU programme would support company in upgrading the business model, business and marketing plan, market validation and would help to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful project implementation will provide much needed tailwind to our company to bring the product to the market.
Avodes has developed an innovative medical device for menstruation - a patented anatomically shaped “moist sponge” made of completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal microflora during most vulnerable period – menstruation. Studies have shown, that fluctuating hormones and the resulting imbalance of vaginal flora cause an increased risk of a yeast infection every month. Unique Avodes biotechnological solution preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It reduces risk of vulvovaginal candidiasis (VVC) by 85 % thus effectively preventing the disease. Avodes is the only medical product designed to prevent infection, rather than deal with the consequences. Avodes effectively disrupts the vicious cycle of ”microbiota disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance” and offers break-through solution which protects women’s health and the environment.
Women Tech EU programme would support company in upgrading the business model, business and marketing plan, market validation and would help to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful project implementation will provide much needed tailwind to our company to bring the product to the market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101071507 |
| Start date: | 01-06-2022 |
| End date: | 30-11-2022 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC) , which affects 3 out of 4 women at some point in their lives. Despite therapeutic advances, VVC remains a common problem worldwide, affecting all strata of society and being the second largest gynaecological infection. If it is left untreated, many complications have been appointed as its consequence, such as infertility, subsequent preterm delivery, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, pelvic abscess, menstrual disorders and miscarriage.Avodes has developed an innovative medical device for menstruation - a patented anatomically shaped “moist sponge” made of completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal microflora during most vulnerable period – menstruation. Studies have shown, that fluctuating hormones and the resulting imbalance of vaginal flora cause an increased risk of a yeast infection every month. Unique Avodes biotechnological solution preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It reduces risk of vulvovaginal candidiasis (VVC) by 85 % thus effectively preventing the disease. Avodes is the only medical product designed to prevent infection, rather than deal with the consequences. Avodes effectively disrupts the vicious cycle of ”microbiota disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance” and offers break-through solution which protects women’s health and the environment.
Women Tech EU programme would support company in upgrading the business model, business and marketing plan, market validation and would help to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful project implementation will provide much needed tailwind to our company to bring the product to the market.
Status
SIGNEDCall topic
HORIZON-EIE-2021-SCALEUP-01-03Update Date
09-02-2023
Images
No images available.
Geographical location(s)
